Lennox-Gastaut Syndrome (LGS)
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Lennox-Gastaut Syndrome (LGS)

What is the definition of Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome is a severe condition characterized by repeated seizures (epilepsy) that begin early in life. Affected individuals have multiple types of seizures, developmental delays, and particular patterns of brain activity measured by a test called an electroencephalogram (EEG). An EEG shows a slow spike-and-wave pattern during wakefulness and generalized paroxysmal fast activity during sleep.

What are the causes of Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome can have many different causes. The disorder likely has a genetic component, although the specific genetic factors are not well understood.

How prevalent is Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome affects an estimated 1 to 2 per million people worldwide. This condition accounts for 3 to 4 percent of cases of epilepsy in children and 1 to 2 percent of cases in adults. For unknown reasons, it appears to be more common in males than in females.

Is Lennox-Gastaut Syndrome (LGS) an inherited disorder?

Most cases of Lennox-Gastaut syndrome are sporadic, which means they occur in people with no history of the disorder in their family. When Lennox-Gastaut syndrome is associated with a genetic change, the variant is usually not inherited but occurs as a random (de novo) event during the formation of reproductive cells (eggs or sperm) in an affected person's parent or during early embryonic development. However, 3 to 30 percent of people with this condition have a family history of some type of epilepsy, indicating that inherited genetic factors may play a role in some cases of Lennox-Gastaut syndrome.

Who are the top Lennox-Gastaut Syndrome (LGS) Local Doctors?
Steve Chung
Elite in Lennox-Gastaut Syndrome (LGS)
Neurology
Elite in Lennox-Gastaut Syndrome (LGS)
Neurology

Banner - University Medical Center Phoenix - Banner - University Medicine Institutes 755

755 East McDowell Road, 
Phoenix, AZ 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

I enjoy patient advocate group activities as well as swimming and hiking. Dr. Chung is rated as an Elite provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Seizures, Epilepsy, Lennox-Gastaut Syndrome (LGS), and Generalized Tonic-Clonic Seizure.

Elite in Lennox-Gastaut Syndrome (LGS)
Pediatrics
Elite in Lennox-Gastaut Syndrome (LGS)
Pediatrics

Young Adult Institute Inc

220 E 42nd St Fl 8, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Steven Wolf is a Pediatrics provider in New York, New York. Dr. Wolf is rated as an Elite provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Lennox-Gastaut Syndrome (LGS), Epilepsy, Seizures, Thrombectomy, and Deep Brain Stimulation.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Lennox-Gastaut Syndrome (LGS)
Neurology
Elite in Lennox-Gastaut Syndrome (LGS)
Neurology

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
Languages Spoken:
English

Anup Patel is a Neurologist in Columbus, Ohio. Dr. Patel is rated as an Elite provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Epilepsy, Lennox-Gastaut Syndrome (LGS), Seizures, and West Syndrome.

What are the latest Lennox-Gastaut Syndrome (LGS) Clinical Trials?
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures

Summary: Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)

Summary: This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics. The eligible participants are expected to participate in the study for a duration of 52 weeks of treatment.

Who are the sources who wrote this article ?

Published Date: May 03, 2023
Published By: National Institutes of Health